title: Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.
abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%-15%) or relapsing-remitting (85%-90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not characteristic, followed by partial or complete recovery. Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur throughout the life of a patient, with periods of partial or complete remission and clinical stability in between. Currently, there are several therapeutic options for MS with disease-modifying properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific receptors on surface of immune cells, changing the expression of several genes and leading to a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompatibility complex class II expression and reduction in inflammatory cells migration into the central nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% (1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 31% more patients relapse-free. In secondary-progressive disease annual rate of progression is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of immunological therapies for this debilitating disease.
authors.affiliation: Pharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, Serbia.
authors.forename: Slobodan M
authors.initials: SM
authors.lastname: Jankovic
references.citation: Health Technol Assess. 2002;6(10):1-73
references.pmid: 12022938
references.citation: Neurology. 2006 Oct 10;67(7):1242-9
references.pmid: 16914693
references.citation: Curr Med Res Opin. 2007 Jun;23(6):1209-15
references.pmid: 17559722
references.citation: Neurology. 2006 Feb 28;66(4):472-6
references.pmid: 16505297
references.citation: Neurology. 2009 Jun 9;72(23):1976-83
references.pmid: 19279320
references.citation: Mult Scler. 2000 Oct;6(5):349-54
references.pmid: 11064446
references.citation: J Neurol. 2008 Oct;255(10):1449-63
references.pmid: 19005625
references.citation: Neurology. 2003 Jan 14;60(1):37-43
references.pmid: 12525715
references.citation: Neurology. 1993 Apr;43(4):655-61
references.pmid: 8469318
references.citation: Pharm Res. 1993 Apr;10(4):567-72
references.pmid: 8483840
references.citation: An Sist Sanit Navar. 1998 Jan-Apr;21(1):15-9
references.pmid: 12891417
references.citation: Neurology. 2001 Oct 23;57(8):1363-70
references.pmid: 11673572
references.citation: Neuroepidemiology. 2008;30(3):140-6
references.pmid: 18382112
references.citation: Eur J Health Econ. 2003;4(1):50-9
references.pmid: 15609169
references.citation: N Engl J Med. 2000 Nov 16;343(20):1430-8
references.pmid: 11078767
references.citation: Neuroepidemiology. 2009;32(4):294-5
references.pmid: 19246934
references.citation: Rev Neurol. 2007 Apr 16-30;44(8):494-8
references.pmid: 17455164
references.citation: Clin Ther. 2008 Jun;30(6):1102-12
references.pmid: 18640466
references.citation: Lancet. 1998 Nov 7;352(9139):1491-7
references.pmid: 9820296
references.citation: Neurology. 1983 Nov;33(11):1444-52
references.pmid: 6685237
references.citation: Mult Scler. 2001 Dec;7(6):349-53
references.pmid: 11795454
references.citation: PLoS One. 2009;4(2):e4565
references.pmid: 19242548
references.citation: Int MS J. 2007 Mar;14(1):29-34
references.pmid: 17509251
references.citation: J Manag Care Pharm. 2009 Sep;15(7):543-55
references.pmid: 19739877
references.citation: Arch Neurol. 1999 Sep;56(9):1079-84
references.pmid: 10488808
references.citation: Vojnosanit Pregl. 2009 Jul;66(7):556-62
references.pmid: 19678581
references.citation: Mult Scler. 2006 Jun;12(3):271-80
references.pmid: 16764339
references.citation: J Interferon Cytokine Res. 2002 Feb;22(2):245-55
references.pmid: 11911808
references.citation: Lab Invest. 2008 Aug;88(8):796-807
references.pmid: 18521063
references.citation: J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):56-60
references.pmid: 14707308
references.citation: Arch Neurol. 1997 May;54(5):531-3
references.pmid: 9152109
references.citation: Lancet. 2007 Aug 4;370(9585):389-97
references.pmid: 17679016
references.citation: Neurology. 1995 Jul;45(7):1277-85
references.pmid: 7617182
references.citation: J Manag Care Pharm. 2007 Apr;13(3):245-61
references.pmid: 17407391
references.citation: CNS Drugs. 2009;23(6):453-62
references.pmid: 19480465
references.citation: J Neurol Sci. 2009 Jul 15;282(1-2):5-11
references.pmid: 19201002
references.citation: Neuroepidemiology. 2007;29(3-4):150-5
references.pmid: 18042998
references.citation: Neuroepidemiology. 2008;31(2):129-37
references.pmid: 18716409
references.citation: Rev Neurol. 2002 Apr 16-30;34(8):732-7
references.pmid: 12080492
references.citation: Biologics. 2009;3:369-76
references.pmid: 19707422
references.citation: Lancet. 2002 Apr 27;359(9316):1453-60
references.pmid: 11988242
references.citation: Int MS J. 2006 May;13(2):58-65
references.pmid: 16696904
references.citation: Ann Neurol. 2007 Apr;61(4):300-6
references.pmid: 17444502
references.citation: Lancet. 2003 Oct 11;362(9391):1184-91
references.pmid: 14568740
references.citation: Expert Rev Neurother. 2005 Mar;5(2):153-64
references.pmid: 15853486
references.citation: Eur J Neurol. 2001 Mar;8(2):141-8
references.pmid: 11284992
references.citation: Acta Neurol Scand Suppl. 2009;(189):27-9
references.pmid: 19566494
references.citation: Lancet Neurol. 2009 Oct;8(10):889-97
references.pmid: 19729344